Resources | Kallyope

JUN 6, 2026

Preclinical Efficacy of Elismetrep, a TRPM8 Blocker, as a Monotherapy and in Combination with Gepants or Triptans

As presented at the 2026 American Headache Society annual meeting in June 2026.

JUN 5, 2026

A novel approach for migraine.

JUN 4, 2026

A Potent and Highly Selective Blocker of the Migraine-Associated Channel TRPM8.

JUN 4, 2026

A Novel Approach for Treating Migraine.

JUN 4, 2026

Predicts Improved Anti-Migraine Efficacy of Elismetrep with an Optimized Formulation Enabling Faster Drug Absorption

JUN 4, 2026

A TRPM8 Migraine-Associated Channel Blocker (MACB), are Well-Suited for a Migraine Therapeutic.

MAY 8, 2026

As presented at the 2026 American Academy of Neurology Annual Meeting in April 2026.